Inflexion Outlines Rosemont Investment And Eyes More Generics Deals

June Deal Was Inflexion’s First In Generics Space

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

In an exclusive interview with Generics Bulletin, Inflexion’s Ben Long reveals his ambitions for newly-acquired UK-based liquids generics specialist Rosemont Pharmaceuticals, including to drive investment in R&D and expand the company’s international footprint.

Interview_2020_2
Thousands of generics remain unavailable in a liquid form, according to Rosemont's new owner Inflexion • Source: Shutterstock

Inflexion, the UK-based private equity that acquired liquid generics specialist Rosemont Pharmaceuticals from Perrigo earlier this year, has underlined its appetite for “kickstarting and quite significantly increasing the investment in licensing and internal research and development at the company,” as it revealed it would “absolutely love to make further investments” in the generics space.

In June, Perrigo announced the immediate sale of Leeds-based Rosemont for £156m ($199m) in cash, with Inflexion capitalizing on Perrigo’s...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Generics

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Nichi-Iko Warns Over Delays From Toyama Plant

Nichi-Iko says that remediation activities at its Toyama plant in the wake of a suspension over GMP violations mean that there may be delays to supply.

More from Products

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Nichi-Iko Has An Ally In Argentina On Infliximab

Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.

Biocon Biologics Refreshes Management

Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.